DEBUTANT Shreyas Iyer and recalled opener Shubman Gill struck half-centuries to help India overcome Kyle Jamieson's terrific display of seam bowling and post 258-4 in the opening Test against New Zealand in Kanpur on Thursday (25).
If Gill's 52 helped India overcome the early loss of opener Mayank Agarwal, Iyer's unbeaten 75 prevented New Zealand from taking control of the contest after Jamieson had prised out three top-order wickets on the opening day.
Ravindra Jadeja also helped himself to an unbeaten 50 having raised 113 runs with Iyer for the burgeoning fifth-wicket stand.
Green Park Stadium's dry, brown pitch had prompted both sides to pick three spinners but it was Jamieson who impressed the most with the ball on a slow track.
"Hopefully the new ball swings a bit in the morning and we can take a few wickets," Jamieson (3-47) told the broadcasters after the day's play.
"India are probably a fraction ahead, but we did well to have them four down."
With several frontline players, including regular captain Virat Kohli, either rested or recuperating, India fielded a new opening pair after opting to bat on a hazy morning in the north Indian city.
Jamieson drew first blood, dismissing Agarwal caught behind for 13, but Gill had a longer, eventful stay.
The 22-year-old was wrongly adjudged lbw even before he could open his account, a decision that had to be overturned after replays confirmed an inside edge before ball hit pad.
Gill, then on six, was also lucky when Ajaz Patel's half-hearted lbw appeal against him was turned down.
New Zealand were left to rue not reviewing that decision as subsequent replays confirmed the ball would have gone on to hit the middle stump.
Gill hit Patel for a six en route to his fifty and his second-wicket stand with Cheteshwar Pujara, who made 26, was worth 61 when Jamieson struck.
The towering seamer dismissed Gill in the first over after lunch when the opener dragged a good-length ball from outside the off-stump onto his stumps.
India's stand-in skipper Ajinkya Rahane fell to Jamieson in similar manner after a fluent 35.
Iyer nearly holed out in the deep trying to score his first Test runs but soon figured out a safer way to do so.
He hit two sixes and seven boundaries and remained on course for a century in his first Test innings. The Test sides had last met in June when New Zealand triumphed in the World Test Championship final.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.